In the last trading session, 37.89 million shares of the Protagenic Therapeutics Inc (NASDAQ:PTIX) were traded. Most recently the company’s share price was $0.38, and it changed around $0.1 or 38.40% from the last close, which brings the market valuation of the company to $2.77M. PTIX currently trades at a discount to its 52-week high of $1.87, offering almost -392.11% off that amount. The share price’s 52-week low was $0.24, which indicates that the current value has risen by an impressive 36.84% since then.

Protagenic Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 1 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended PTIX as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight.

Protagenic Therapeutics Inc (NASDAQ:PTIX) trade information

Instantly PTIX has showed a green trend with a performance of 38.40% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 0.3710 on recent trading daydecreased the stock’s daily price by -2.43%. The company’s shares are currently down -21.96% year-to-date, but still up 59.33% over the last five days. On the other hand, Protagenic Therapeutics Inc (NASDAQ:PTIX) is 3.63% up in the 30-day period.

Protagenic Therapeutics Inc (NASDAQ:PTIX)’s Major holders

Vanguard Extended Market Index Fund and Fidelity NASDAQ Composite Index Fund were the top two Mutual Funds as of Sep 30, 2024. The former held 32.0 shares worth $12804.0, making up 0.44% of all outstanding shares. On the other hand, Fidelity NASDAQ Composite Index Fund held roughly 22.88 shares worth around $9156.0, which represents about 0.32% of the total shares outstanding.